Crispr Therapeutics AG (NASDAQ:CRSP) shares rose 6.1% on Thursday . The stock traded as high as $30.70 and last traded at $30.08. Approximately 576,104 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 1,092,983 shares. The stock had previously closed at $28.34.
CRSP has been the topic of several research analyst reports. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research report on Sunday, December 10th. BidaskClub cut shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Piper Jaffray Companies initiated coverage on shares of Crispr Therapeutics in a research report on Friday, December 22nd. They issued an “overweight” rating on the stock. Oppenheimer initiated coverage on shares of Crispr Therapeutics in a research report on Thursday, December 7th. They issued a “hold” rating on the stock. Finally, SunTrust Banks restated a “hold” rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a research report on Friday, November 10th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $22.81.
The stock has a market capitalization of $1,380.00 and a PE ratio of -94.00.
In related news, major shareholder Corp /De/ Celgene sold 22,759 shares of the firm’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $19.10, for a total value of $434,696.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tyler Dylan-Hyde sold 66,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $28.03, for a total value of $1,849,980.00. Following the completion of the sale, the insider now directly owns 25,204 shares of the company’s stock, valued at approximately $706,468.12. The disclosure for this sale can be found here. Insiders have sold 2,234,504 shares of company stock worth $44,388,553 over the last quarter. Company insiders own 39.98% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN lifted its stake in Crispr Therapeutics by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after acquiring an additional 6,560 shares during the period. Capital Investment Advisory Services LLC purchased a new stake in Crispr Therapeutics in the third quarter worth $193,000. Ark Investment Management LLC purchased a new stake in Crispr Therapeutics in the second quarter worth $206,000. Moloney Securities Asset Management LLC purchased a new stake in Crispr Therapeutics in the third quarter worth $235,000. Finally, Creative Planning purchased a new stake in Crispr Therapeutics in the fourth quarter worth $243,000. 21.91% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/18/crispr-therapeutics-crsp-stock-price-up-6-1.html.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.